Saturday 17 October 2026
Export TIL’s income statement to Excel — free account
Instil Bio, Inc.
In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
5.91
0.22
−3.59%
Follow TIL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 288.40 | 9.42 | 6.08 | 7.28 | 10.17 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 589.80 | 379.40 | 18.54 | 92.00 | 42.79 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 150 | 412 | 192 | 49 | 14 | 17 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (7) | (38) | (157) | (225) | (156) | (74) | (71) | |||||
| EBT margin, % | — | — | — | 0.00 | (27,236.96) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (7) | (38) | (157) | (223) | (156) | (74) | (71) | |||||
| Depreciation | — | — | — | 0 | 0 | 3 | 22 | 5 | 4 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (11.01) | (47.18) | (29.60) | (34.40) | (24.00) | (11.39) | (10.70) | |||||
| Cash flow | — | — | — | (8.93) | (37.02) | (23.05) | (27.82) | (12.61) | (8.56) | (5.49) | |||||
| Capex | — | — | — | (0.35) | (63.53) | (10.91) | (13.06) | (3.18) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (9.29) | (100.55) | (33.96) | (40.88) | (15.79) | (8.56) | (5.49) | |||||
| Book value | — | — | — | (11.63) | (49.50) | 104.76 | 56.15 | 34.72 | 26.03 | 17.08 | |||||
| Shares, m | — | — | — | 1 | 1 | 5 | 6 | 7 | 7 | 7 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | ||||
| P/S | — | — | — | — | 3,065.12 | — | — | — | — | — | |||||
| P/B | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | 1,313.57 | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | (2.25) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (5) | (30) | (122) | (180) | (82) | (56) | (37) | ||||
| Capex | — | — | — | 0 | (51) | (58) | (85) | (21) | — | — | |||||
| Free cash flow | — | — | — | (6) | (80) | (180) | (265) | (103) | (56) | (37) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 8 | 233 | 423 | 237 | 150 | 117 | 187 | ||||
| Total debt | — | — | — | — | — | — | 72 | 81 | 84 | 85 | |||||
| Net debt | — | — | — | (9) | (242) | (454) | (189) | (70) | (31) | 9 | |||||
| Shareholders’ equity | — | — | — | (7) | (40) | 555 | 364 | 226 | 169 | 114 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (137.65) | (22.98) | (33.76) | (40.87) | (38.65) | (25.16) | (30.56) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (96.17) | (80.86) | (64.02) | (33.19) | (40.13) | |||||
| ROE | — | — | — | 28.06 | 162.35 | (60.82) | (48.58) | (52.96) | (37.51) | (50.39) | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Sep 2020
Charts ten years each
Instil Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SER Serina Therapeutics, Inc. | $45.5M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $44.8M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $44.5M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $43.2M | — (loss-making) | — (loss-making) | −66.34% (below 0%: shrinking) | n/m | +148.35% (above 0%: growing) | 62.25% | (263.47%) | Compare |
| DWTX Dogwood Therapeutics, Inc | $42.5M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| SGMOQ Sangamo Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | −77.60% (below 0%: shrinking) | n/m | +26.21% (above 0%: growing) | 100.00% | (2,215.40%) | Compare |
| VERU Veru Inc. | $41.6M | — (loss-making) | — (loss-making) | +287.06% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 34.92% | 0.00% | Compare |
| TIL Instil Bio, Inc. | $41.6M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | |
| GRCE Grace Therapeutics, Inc. | $41.0M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $42.8M | — | — | +287.06% | — | +5.29% | 48.59% | 0.00% |
Instil Bio, Inc. (TIL) key facts
- Concern: Instil Bio, Inc. reported a net loss of $71.4 million, or a loss of $10.70 per share, for fiscal 2025.
- Instil Bio, Inc. (TIL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TIL traded at $5.91, a market capitalization of $41.6 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 290× sales.
- Return on equity was −50.4% and debt-to-equity 0.79.